Ophthalmology Times

AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD

At the American Academy of Ophthalmology (AAO) 2026 Retina Subspecialty Day in New Orleans, Charles C. Wykoff, MD, PhD, ...
Healio

FIREFLEYE next study shows long-term efficacy, safety of aflibercept 0.4 mg in ROP

Aflibercept 0.4 mg intravitreal injection in preterm and low birthweight infants with acute-phase retinopathy of prematurity ...
Yahoo Finance

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Regeneron Eylea feels the pinch as Kodiak advances extended dosing for eye drug

Regeneron Pharmaceuticals Inc.’s REGN stock is trading lower on Monday, probably in reaction to positive data from Kodiak ...
Yahoo Finance

Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
Nasdaq

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...
FiercePharma

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)

TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the ...
FiercePharma

EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan

TARRYTOWN, N.Y. -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that EYLEA ® (aflibercept) Injection has received approval for the treatment of patients with neovascular age-related macular ...
markets.financialcontent

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- ...
JD Supra

Phase 1 Clinical Trial of Aflibercept (Eylea®) Biosimilar Completed by Alteogen

Alteogen recently announced that it has successfully completed a Phase 1 clinical trial for its Eylea® biosimilar, ALT-L9. Alteogen conducted the clinical trials in South Korea, where its headquarters ...
markets.financialcontent

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. First and only FDA-approved treatment for RVO ...